AI Generated by Fortune India
Austrian biotech firm Efferon enters India with blood purification devices for sepsis treatmentNovember 18, 2026, 09:42 IST
Loading AI Hub...
Disclaimer : Certain content on this page, including summaries, timelines, FAQs, glossaries, highlights, insights, and other supplementary informational features, maybe generated or assisted by artificial intelligence tools. While reasonable efforts are made to review and verify such content, AI generated output may occasionally contain errors, omissions or inconsistencies. Readers are advised to independently verify any information before relying upon them for professional, legal, financial, medical or other decisions. The publisher along with its affiliates and contributors do not warrant accuracy of AI-generated content and disclaim any liability, loss or damage arising from its use.

Austrian biotech firm Efferon enters India with blood purification devices for sepsis treatment

/2 min read

ADVERTISEMENT

Efferon has announced the registration of its Efferon LPS medical device in India.
Austrian biotech firm Efferon
Helmier is a medical disposables and equipment manufacturer focused on anaesthesia, critical care and surgical solutions. Credits: Alamy

Austrian biotech company Efferon AG has entered the Indian market through a partnership with medical devices maker Helmier to supply blood purification devices for critical care involving severe sepsis and systemic inflammation.

Efferon has announced the registration of its Efferon LPS medical device in India. Under the partnership, Helmier will handle regulatory support, imports, supply and distribution of Efferon products, besides providing healthcare professional training, technical assistance and clinical support.

Sign up for Fortune India's ad-free experience
Enjoy uninterrupted access to premium content and insights.

The partnership will introduce Efferon’s blood purification technologies to Indian hospitals treating patients with severe sepsis and septic shock. The companies will combine product supplies with clinician training and on-ground technical support.

Efferon, which is headquartered in Austria, has an office in the US and manufacturing facilities in Estonia and Latvia. Its technology is approved and used across Europe, with more than 30,000 treatments delivered across 45 countries, including Australia, the UK, Germany, and Saudi Arabia.

Helmier is a medical disposables and equipment manufacturer focused on anaesthesia, critical care and surgical solutions.

Helmier will lead Efferon’s market development in India, including regulatory activities, hospital outreach, product launch and ongoing service support.

“Efferon's devices will benefit India most when the launch is supported by hands-on training, reliable technical support,” said Raghuram Iyer, co-founder and business unit head of Helmier.

Sepsis is a life-threatening condition in which the body’s response to infection damages its own tissues and organs. Treatment typically involves antibiotics, source control and organ support, with blood purification forming part of the broader critical-care strategy.

“Sepsis does not stop at borders. The pandemic made that painfully clear: estimated global cases of sepsis rose from 128 million in 2019 to 166 million in 2021,” said Dima Romashin, CEO and co-founder of Efferon. He said the partnership would combine the company’s technology and clinical experience with Helmier’s understanding of the Indian hospital market.

Efferon’s portfolio comprises two multimodal therapeutic hemoadsorption devices. Efferon LPS combines endotoxin and cytokine adsorption, enabling the simultaneous removal of bacterial endotoxins and excess inflammatory mediators from the bloodstream.

The second product, Efferon NEO, is designed for neonates, children and adolescents with lower circulating blood volumes. It received the CE MDR mark in April 2026, supported by findings from the multicentre LASSO NEO study (NCT05707494), which evaluated the technology in children aged one month to 18 years.

The study reported 28-day mortality of 9% among patients treated with Efferon NEO, compared with 35% in the control group.

Follow Fortune IndiaNews, insights and conversations that matter, on your favourite platforms.